You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Thursday, November 17, 2022
11 am EST | 8 am PST | 4 pm GMT



The demand for gene therapy viral vectors requires manufacturing processes to scale up to 2000 L. Viral vector production at this scale requires a 9- to 12-day seed train with two to three seeding bioreactors, increasing the risk of failure and manufacturing cost. Perfusion-based cell culture intensification techniques shorten and simplify the seed train for recombinant proteins and monoclonal antibodies production by reducing time, equipment, bioreactor size and cost while increasing the potential number of batches per year. This webinar will discuss similar efficiency gains for three different viral vectors (lentivirus, AAV8 and AAV9) through intensification using  KrosFlo® TFDF® Technology that resulted in reduce train vessel number, N-1 vessel size, media volume and time.


riaj.pngRiaj Mahamud
Sr. Scientist Cell Culture-Viral Vector, Advanced Bioprocess Applications

Riaj Mahamud is Sr. Scientist Cell Culture-Viral Vector, Advanced Bioprocess Applications at Repligen.
He has industrial experience and expertise in molecular biology, cell culture, cell line development, and viral vector upstream process development. Riaj holds a PhD in Cell Biology from the University of Oklahoma HSC and received a postdoctoral training from Oklahoma Medical Research Foundation. He started his career in the pharmaceutical industry as a scientist cell line development at the Takeda Pharmaceutical Ltd. In his current role at Repligen, he is expanding his expertise in the development of advanced bioprocess applications and technologies focusing on TFDF-based cell culture intensification and viral vector manufacturing processes.